summary: In this study the authors aimed to investigate the effects of oral pioglitazone, a drug that has been shown to have anti-inflammatory and neuroprotective effects, in people with relapsing-remitting MS, when added to IFN beta. After one year of treatment, though no differences were observed between the two groups of treatment (IFN+pioglitazone and IFN+placebo) from the clinical point of view, some differences were observed in terms of MRI parameters. These findings would suggest hints of efficacy favouring the pioglitazone treatment. Further studies are needed to establish clinical efficacy of pioglitazone.

authors: Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL

source: J Neuroimmunol. 2009 May 14

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: